Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

SAs CASI 2nd Q PR link is incomplete

I was reading CASIs 2nd Q PR via Seeking Alpha and realized it was missing the first bullet.

- China FDA (CFDA) import drug registration priority review of EVOMELA® in progress and preparations continue for its commercial launch in China
- CFDA review in progress for Marqibo® and Zevalin®
- Entered into an agreement for the manufacturing of entecavir and cilostazol
- Added to Russell 2000®, 3000® and Microcap® Indexes

My initial reaction was that's pretty bush league for a pharma company to skip their most important highlight. And my second reaction was let me go to CASIs web site and see. They had the first bullet that I posted above. Here's the like to get you to CASIs PR

http://www.casipharmaceuticals.com/investor-relations/news/casi-pharmaceuticals-announces-second-quarter-and-first-half-2018